Navigation Links
Einstein College of Medicine receives $5.7 million for developmental disabilities research

October 17, 2011 (BRONX, NY) The Eunice Kennedy Shriver National Institute for Child Health and Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University $5.7 million to fund the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC). The grant supports Einstein's ongoing efforts to improve the lives of children with intellectual and developmental disabilities (IDD) through combined basic science research and clinical practice.

Occurring in an estimated 10 percent of the population, IDDs constitute some of the most significant health conditions in children. They represent a diverse group of chronic conditions such as autism spectrum disorders and Down syndrome that can limit daily function and impede mobility, language and more. IDDs can begin anytime during a child's development up to 22 years of age, and usually last a lifetime.

"The Rose F. Kennedy Center was founded more than 40 years ago as one of the nation's flagship centers on mental retardation," said Steven Walkley, D.V.M., Ph.D., director of Einstein's IDDRC and professor in the Dominick P. Purpura Department of Neuroscience. "This grant allows us to intensify the translational research we've been doing, which when coupled with clinical care, may lead to a better understanding of the causes, consequences and potential treatments of these conditions." Dr. Walkley is also professor of pathology and in the Saul R. Korey Department of Neurology. John Foxe, Ph.D., director of research at Einstein's Children's Evaluation and Rehabilitation Center (CERC), will serve as the center's associate director.

Einstein's IDDRC is an interdisciplinary collaboration involving numerous academic departments including neuroscience, genetics, neurology and pediatrics along with the Gruss Magnetic Resonance Research Center and CERC, which is directed by Robert Marion, M.D., the Ruth L. Gottesman Professor of Developmental Pediatrics. Its six scientific cores are designed to provide the means for human and animal phenotyping, neuron and whole brain imaging, cell and tissue manipulation, and genetic analysis.

There will be four main areas of focus for the IDDRC that draw on Einstein's strengths in basic science research and extensive clinical practice. The themes are autism spectrum disorders, neurogenetic and seizure disorders, nutritional and environmental determinants of brain development, and deafness and communication disorders.

"While tremendous strides have been made over the past four decades to identify and treat these disorders, it is critical to leverage the most recent advances in research and technologies to better understand what causes them and provide more targeted and effective therapies," explained Dr. Walkley. "Through the combined efforts of our faculty researchers and clinicians, we hope to improve methods of diagnosis, prevention and treatment."

Einstein's IDDRC will also continue to build and sustain outreach programs to help alleviate some of the burden of IDDs on families in the Bronx, which is one of the most ethnically diverse and poorest urban counties in the United States.


Contact: Kim Newman
Albert Einstein College of Medicine

Related medicine news :

1. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
2. Einstein scientists find crucial molecule involved in spread of breast cancer
3. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
4. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
5. Feinstein scientists identify abnormal disease pathway in dystonia
6. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
7. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
9. Feinstein Institute to share $5M US Department of Defense grant
10. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
11. Einstein awarded NIH grant to study drug-resistant TB
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: